How do real tumors become resistant to cisplatin?

Area of Science:

• Oncology
• Cancer Biology
• Genetics

Background:

• Platinum compounds are standard chemotherapy agents, but acquired resistance limits their efficacy.
• Lab studies identified diverse resistance mechanisms in cultured tumor cells.
• Homology-directed DNA repair (HR) is crucial for repairing DNA damage caused by platinum drugs.

Purpose of the Study:

• To investigate cisplatin resistance in BRCA1-deficient mouse mammary tumors.
• To determine if established in vitro resistance mechanisms apply to in vivo tumor settings with irreversible DNA repair defects.
• To explore the role of HR in platinum sensitivity and resistance in real tumors.

Main Methods:

• Analysis of mouse mammary tumors with irrepairable Brca1 null alleles.
• Observation of tumor response and relapse patterns following cisplatin treatment.
• Review of clinical data from ovarian cancer patients with BRCA2 defects and acquired platinum resistance.

Main Results:

• Brca1-deficient mouse tumors did not develop resistance to cisplatin, despite shrinking with treatment and always relapsing.
• These tumors invariably became resistant to other anti-cancer drugs.
• Ovarian cancer patients initially sensitive to platinum due to BRCA2 defects developed resistance via secondary mutations restoring BRCA2 function.

Conclusions:

• An irreversible defect in HR, as seen in Brca1-deficient tumors, prevents cells from overcoming cisplatin-induced DNA damage.
• Functional HR is essential for tumor cell survival against platinum-induced DNA lesions.
• Proliferating cells may lack alternative mechanisms to escape cisplatin damage once HR is irreversibly inactivated.